Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NO to win. CIN to lose.
Thanks,
GB to win. NYG to lose.
Thanks,
NE to win. NYJ to lose.
Thanks.
TEN to win JAX to lose.
Thanks.
McIlroy, Schauffele, Berger, Cantlay, Matsuyama. 281.
KC to win. CLE to lose.
Thanks, Eli....
Morikawa, Reed, Schauffele, Champ, Finau, Day, Casey, Cantlay, Scott, Woods
Eli, please replace Schauffele with Mickelson. Thanks.
Notable group pairings and tee times...
https://www.pgachampionship.com/news-media/groups-and-tee-times-opening-rounds
McIlroy, Koepka, Morikawa, DeChambeau,Schauffele. 271.
Nice post...I’m just a lurker here but ‘recognize’ everyone.
Happy birthday, wade.
PONTE VEDRA BEACH, Fla. – The PGA Tour has reversed course and announced the cancellation of The Players as well as the next three events on the schedule because of the coronavirus outbreak.
The late-night decision comes less than 12 hours after Tour commissioner Jay Monahan said that the circuit’s flagship event would continue for the next three rounds but without spectators.
Players were notified via text at about 9:50 p.m. ET Thursday that the tournament had been scrapped because of the "rapidly changing situation" regarding COVID-19. In a follow-up text, the Tour said that the next three events (Valspar Championship, WGC-Dell Match Play and Valero Texas Open) were also canceled.
McIlroy, Reed, Rose, Dechambeau, Scott
279
37-27, KC over
Thanks!
KC under, SF over
Thanks!
SF, BAL, KC, SEA all under
Thanks!
HOU-u, NE-u, NO-o, SEA-u
Thanks!
NO to win. LAC to lose
Thanks!
DEN to win. LAR to lose.
Thanks!
SF to win. IND to lose.
Thanks!
GB to win. DET to lose.
Thanks!
CAR to win. BUF to lose.
Thanks!
CLE to win. CAR to lose.
Thanks,
OAK to win. DEN to lose.
Thanks!
IND to win. ATL to lose
Thanks!
I love a Seahawk win, no matter how they get it. Go ‘hawks!
SEA to win. ARI to lose.
Thanks!
MIN to win. CLE to lose.
Thanks!
BUF to win. MIA to lose.
Thank you!
NE to win. PIT to lose.
Thanks!
Oops. WAS to lose.
Thanks.
KC to win. NYJ to lose
Thanks!
LAR to win. OAK to lose.
Thanks!
DAL to win JETS to lose.
Thanks!
BAL to win. JAX to lose.
Thanks!
PHI to win. CIN to lose.
Thanks!
Koepka, DJ, Rose, Fleetwood, Kisner, Pierce, Matsuyama, Glover, Reed, Stenson,
McIlroy, Stenson, Cantlay, Reed, Janewattananond. 275
Thanks!
Are you reading the other SGMO site I sent you in private message? Check your mailbox.
“Jefferies: SGMO providing reasons for pts+docs to hesitate to use Valrox.
New ISTH HemeA Data Stand Out W/ Consistent
Efficacy, Durability, and Safety
July 7, 2019
Key Takeaway
SGMO reported new '525 hemeA data at ISTH that were in-line w/ our expectations here
-- data showed durable F8 in follow-up for two high-dose (3E13) pts and consistent F8
efficacy in two new 3E13 pts w/ favorable safety. Data add more support to case for
'525 being differentiated -- tracking superior to Valrox and SPK-8011; more data at ASH.
SGMO noted in their PR they are working w/ PFE to move '525 into a registrational trial. RMAT
announced too.
Recall, normal F8 levels were achieved rapidly for the two initial pts dosed at 3E13 (last
cut reported on 4/2); the ISTH cut shows that F8 levels were maintained in the longerterm
follow up. For these two pts both reached a normal F8 range (50-170%) w/in 6 wks
w/ F8 levels tracking better than both BMRN's Valrox and Roche/ONCE's SPK-8011 w/
in this timeframe; longer-term data showed normal F8 was maintained out to 24 and 19
wks for the two pts (#7 and #8, respectively). Notably, the follow-up data also showed at
the 1E13 dose pt #6 had F8 durable to wk 52 and #5 some durability to wk 32.
First look at two new expansion pts who received high-dose 3E13 (pts #9 and 10) showed
consistent F8 kinetics w/ two initial 3E13 pts. W/ new pts #9 and 10 we saw F8 ramp
up rapidly post tx; notably, pt #9 had the lowest baseline F8 (of the 4 high-dose pts), and
showed rapid F8 increase after wk 1, which continued to ramp up at wks 2-5. The slide
deck noted after the ISTH cut pt #9 reached normal F8 at wk 7. Pt #10 has only been on tx
for 3 wks, and this pt is showing a similar trajectory. Together, the data from the two new
pts support consistency, and total follow-up support durability, giving us greater confidence.
Also, the total '525 safety profile so far looks good, even w/ no prophylactic steroid used.
No new notable safety events were observed; in the two new pts (according to the PR)
there was one add'l transient Gr1 ALT (both ALTs managed w/ oral tapering) and a new
Gr2 pyrexia. We view the overall safety profile so far as a favorable.
What is SGMO doing differently to stack up better vs the rest? Safety and efficacy may
go hand-in-hand -- better SGMO profile could be driven in part by the low total viral load
used (vs Valrox), a benefit that resonates w/ experts... and has manufacturing advantages
too, which may reflect a better transgene/expression system w/ '525 that enables '525
to come out on top of SPK-8011. SGMO has highlighted their modified F8 transgene
including optimized liver-specific promoter and cassette, which led to better preclin NHP
data vs BMRN and ONCE -- seems to be panning out in the clinic. Could also be related
to the different AAV serotypes used, which may improve '525 tropism/transduction.
SGMO's high-dose data are early and small #s, but looking relatively good so far. BMRN
ahead, but SGMO providing reasons for pts+docs to hesitate to use Valrox.
RMAT, add'l data at ASH, and talk about a registrational path. SGMO is expected to
present add'l data (follow-up+new pts) at ASH -- PR notes pt 11 is expected to be treated
soon (may treat two more at 3E13 for 7 total). The PR also announced RMAT, which we
view as an important positive that should help w/ advancement to a registrational.”